JP2015506985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506985A5 JP2015506985A5 JP2014556793A JP2014556793A JP2015506985A5 JP 2015506985 A5 JP2015506985 A5 JP 2015506985A5 JP 2014556793 A JP2014556793 A JP 2014556793A JP 2014556793 A JP2014556793 A JP 2014556793A JP 2015506985 A5 JP2015506985 A5 JP 2015506985A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- piperidin
- alkyl
- ring
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 (cyclopropyl)- Chemical class 0.000 claims 23
- 150000001875 compounds Chemical group 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- AHIHJODVQGBOND-UHFFFAOYSA-M propan-2-yl carbonate Chemical compound CC(C)OC([O-])=O AHIHJODVQGBOND-UHFFFAOYSA-M 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 0 C*(CCC1=Cc(cccc2)c2NC1=O)c(cc1C=C2*)ccc1NC2=O Chemical compound C*(CCC1=Cc(cccc2)c2NC1=O)c(cc1C=C2*)ccc1NC2=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597695P | 2012-02-10 | 2012-02-10 | |
| US61/597,695 | 2012-02-10 | ||
| US201261667821P | 2012-07-03 | 2012-07-03 | |
| US61/667,821 | 2012-07-03 | ||
| PCT/US2013/025639 WO2013120104A2 (en) | 2012-02-10 | 2013-02-11 | Modulators of methyl modifying enzymes, compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506985A JP2015506985A (ja) | 2015-03-05 |
| JP2015506985A5 true JP2015506985A5 (OSRAM) | 2016-03-31 |
| JP5989805B2 JP5989805B2 (ja) | 2016-09-07 |
Family
ID=48948171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556793A Active JP5989805B2 (ja) | 2012-02-10 | 2013-02-11 | メチル基変更酵素の調節物質、組成物及びその使用 |
| JP2015557190A Active JP5989923B2 (ja) | 2012-02-10 | 2014-02-11 | メチル基変更酵素の調節物質、組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557190A Active JP5989923B2 (ja) | 2012-02-10 | 2014-02-11 | メチル基変更酵素の調節物質、組成物及びその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9085583B2 (OSRAM) |
| EP (1) | EP2812001B1 (OSRAM) |
| JP (2) | JP5989805B2 (OSRAM) |
| AR (1) | AR094755A1 (OSRAM) |
| AU (1) | AU2013216721B2 (OSRAM) |
| BR (1) | BR112015018508B1 (OSRAM) |
| CA (1) | CA2862289C (OSRAM) |
| CY (1) | CY1119060T1 (OSRAM) |
| DK (1) | DK2953941T3 (OSRAM) |
| EA (1) | EA029089B9 (OSRAM) |
| ES (1) | ES2632241T3 (OSRAM) |
| HR (1) | HRP20171030T1 (OSRAM) |
| LT (1) | LT2953941T (OSRAM) |
| MX (1) | MX363392B (OSRAM) |
| MY (1) | MY172156A (OSRAM) |
| NZ (1) | NZ628762A (OSRAM) |
| PT (1) | PT2953941T (OSRAM) |
| SM (1) | SMT201700340T1 (OSRAM) |
| UA (1) | UA117362C2 (OSRAM) |
| WO (1) | WO2013120104A2 (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9085583B2 (en) * | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| MA38341B1 (fr) * | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP2970305B1 (en) * | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| CN105473580A (zh) | 2013-07-10 | 2016-04-06 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste同源物增强子2抑制剂 |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| WO2015023915A1 (en) * | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015078417A1 (zh) * | 2013-11-29 | 2015-06-04 | 四川好医生药业集团有限公司 | 吡咯并嘧啶化合物及其在制备降血糖药物中的用途 |
| EP3160940A4 (en) * | 2014-06-25 | 2018-05-02 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| MA40848A (fr) * | 2014-10-28 | 2021-05-05 | Glaxosmithkline Ip No 2 Ltd | Inhibiteurs d'ezh2 (enhancer of zeste homolog 2) |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US20180037568A1 (en) * | 2015-02-13 | 2018-02-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| US20180214519A1 (en) | 2015-07-24 | 2018-08-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
| CN108136011A (zh) | 2015-08-03 | 2018-06-08 | 星座制药公司 | Ezh2抑制剂和调节性t细胞功能的调制 |
| WO2017025493A1 (en) * | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Quinoline ezh2 inhibitors |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) * | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| KR20180058829A (ko) | 2015-10-06 | 2018-06-01 | 에피자임, 인코포레이티드 | Ezh2 억제제로 수모세포종을 치료하는 방법 |
| US20180321256A1 (en) | 2015-11-05 | 2018-11-08 | Epizyme, Inc. | Flow cytometry for monitoring histone h3 methylation status |
| EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| SG11201807965YA (en) | 2016-03-15 | 2018-10-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| HRP20201131T1 (hr) | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| JP2019521988A (ja) | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| WO2018102687A2 (en) | 2016-12-02 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3050696A1 (en) | 2017-01-20 | 2018-07-26 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018231973A1 (en) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| US20210161883A1 (en) | 2017-07-10 | 2021-06-03 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitor-induced gene expression |
| US11459315B2 (en) | 2017-11-09 | 2022-10-04 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA3082287C (en) | 2017-11-14 | 2023-02-28 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| CN111757734A (zh) | 2017-12-28 | 2020-10-09 | 星座制药公司 | 通过组合疗法的ezh2抑制剂的药代动力学增强 |
| PT4043466T (pt) | 2018-01-31 | 2024-10-14 | Mirati Therapeutics Inc | Inibidores de prc2 |
| CA3093315A1 (en) | 2018-03-14 | 2019-09-19 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors |
| CN119954787A (zh) * | 2018-04-18 | 2025-05-09 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| CN113166137B (zh) | 2018-09-19 | 2024-08-16 | 比奥根Ma公司 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 |
| AR116898A1 (es) * | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| EP3891146B1 (en) | 2018-12-05 | 2023-09-27 | Biogen MA Inc. | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl derivatives useful as o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| WO2020139339A1 (en) | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN110357840B (zh) * | 2019-01-22 | 2022-04-12 | 石家庄和中科技有限公司 | 4-糠硫基戊酮-2的制备方法 |
| AR117989A1 (es) | 2019-02-04 | 2021-09-08 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico |
| EP3935055A1 (en) | 2019-03-08 | 2022-01-12 | Biogen MA Inc. | Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| EP4003343A1 (en) * | 2019-07-24 | 2022-06-01 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition in combination therapies for the treatment of cancers |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| UY38934A (es) | 2019-10-29 | 2021-05-31 | Biogen Ma Inc | Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica |
| CN116917284A (zh) | 2020-08-03 | 2023-10-20 | 渤健马萨诸塞州股份有限公司 | O-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂的结晶形式 |
| WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
| CN118026860A (zh) * | 2024-02-05 | 2024-05-14 | 福建福瑞明德药业有限公司 | 一种3-[1-(二甲基氨基)乙基]苯酚的制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| KR100537843B1 (ko) | 1996-07-22 | 2006-04-28 | 다이이치 아스비오파마 가부시키가이샤 | 아릴피페리디놀및아릴피페리딘유도체및이들을함유하는약제 |
| HRP20040213A2 (en) | 2001-09-04 | 2005-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| MXPA03000145A (es) | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| CN101014571A (zh) | 2004-01-30 | 2007-08-08 | 默克公司 | 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物 |
| CA2564085C (en) | 2004-04-30 | 2013-04-02 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| US7563589B2 (en) | 2004-06-01 | 2009-07-21 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| CN101263121A (zh) * | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
| EP1915155A1 (en) | 2005-08-03 | 2008-04-30 | Boehringer Ingelheim International GmbH | Dihydropteridinones in the treatment of respiratory diseases |
| EP1960547A2 (en) | 2005-12-08 | 2008-08-27 | Novartis AG | Effects of inhibitors of fgfr3 on gene transcription |
| WO2008054154A1 (en) | 2006-11-03 | 2008-05-08 | Korea Research Institute Of Chemical Technology | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same |
| CA2676039A1 (en) | 2007-01-19 | 2008-07-24 | The Regents Of The University Of Michigan | Adrb2 cancer markers |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| US20100298270A1 (en) | 2007-07-23 | 2010-11-25 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| FR2922209B1 (fr) | 2007-10-12 | 2010-06-11 | Sanofi Aventis | 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. |
| US20100261743A1 (en) | 2007-12-06 | 2010-10-14 | Glaxosmithkline Llc | Novel seh inhibitors and their use |
| TW200944506A (en) * | 2008-03-26 | 2009-11-01 | Takeda Pharmaceutical | Substituted pyrazole derivatives and use thereof |
| US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| EP2365749A4 (en) | 2008-11-13 | 2012-05-30 | Merck Sharp & Dohme | Quinolone NEURO PEPTIDE-S-Receptor Antagonists |
| WO2011055270A1 (en) | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| US8468343B2 (en) | 2010-01-13 | 2013-06-18 | Futurewei Technologies, Inc. | System and method for securing wireless transmissions |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| US8575203B2 (en) | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US8637509B2 (en) * | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| EP2566327B1 (en) * | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| WO2012024543A1 (en) | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012051492A2 (en) | 2010-10-14 | 2012-04-19 | University Of Georgia Research Foundation, Inc. | Compounds and methods for inhibiting hiv latency |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| ES2607064T3 (es) | 2010-12-01 | 2017-03-29 | Glaxosmithkline Llc | Indoles |
| CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| JP2014511389A (ja) * | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| KR20140095073A (ko) * | 2011-11-04 | 2014-07-31 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 치료 방법 |
| WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013067300A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20130230511A1 (en) | 2012-02-03 | 2013-09-05 | Board Of Regents, The University Of Texas System | Biomarkers for response to tyrosine kinase pathway inhibitors in cancer |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2825161B1 (en) | 2012-03-12 | 2019-01-02 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| CN104768555B (zh) | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
| PL3628670T3 (pl) | 2012-04-13 | 2023-02-20 | Epizyme, Inc. | Postać soli dla inhibicji ezh2 |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014049488A1 (en) * | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| SG10201705989YA (en) * | 2012-10-15 | 2017-08-30 | Epizyme Inc | Substituted benzene compounds |
| CN103794728A (zh) | 2012-10-30 | 2014-05-14 | 中国科学院长春光学精密机械与物理研究所 | 高导电性有机透明导电薄膜的制备方法 |
| CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
| WO2014077784A1 (en) | 2012-11-19 | 2014-05-22 | Agency For Science, Technology And Research | Method of treating cancer |
| US20150292030A1 (en) | 2012-11-27 | 2015-10-15 | Board Of Regents, The University Of Texas System | Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer |
| WO2014092905A1 (en) | 2012-12-10 | 2014-06-19 | Children's Medical Center Corporation | Methods and assays for combination treatment of cancer |
| WO2014100080A1 (en) | 2012-12-19 | 2014-06-26 | Glaxosmithkline Llc | Combination |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP2970305B1 (en) * | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| HK1214815A1 (zh) * | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| EP3022195A2 (en) * | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015023915A1 (en) * | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US9374093B2 (en) | 2014-01-10 | 2016-06-21 | Freescale Semiconductor, Inc. | Capacitively coupled input buffer |
| EP3160940A4 (en) * | 2014-06-25 | 2018-05-02 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
-
2013
- 2013-02-11 US US14/377,214 patent/US9085583B2/en active Active
- 2013-02-11 AU AU2013216721A patent/AU2013216721B2/en active Active
- 2013-02-11 CA CA2862289A patent/CA2862289C/en active Active
- 2013-02-11 EP EP13746186.9A patent/EP2812001B1/en active Active
- 2013-02-11 NZ NZ628762A patent/NZ628762A/en unknown
- 2013-02-11 WO PCT/US2013/025639 patent/WO2013120104A2/en not_active Ceased
- 2013-02-11 JP JP2014556793A patent/JP5989805B2/ja active Active
-
2014
- 2014-02-11 MX MX2015010377A patent/MX363392B/es unknown
- 2014-02-11 EA EA201591474A patent/EA029089B9/ru unknown
- 2014-02-11 SM SM20170340T patent/SMT201700340T1/it unknown
- 2014-02-11 MY MYPI2015001865A patent/MY172156A/en unknown
- 2014-02-11 DK DK14708987.4T patent/DK2953941T3/en active
- 2014-02-11 JP JP2015557190A patent/JP5989923B2/ja active Active
- 2014-02-11 AR ARP140100433A patent/AR094755A1/es active IP Right Grant
- 2014-02-11 ES ES14708987.4T patent/ES2632241T3/es active Active
- 2014-02-11 BR BR112015018508-8A patent/BR112015018508B1/pt active IP Right Grant
- 2014-02-11 US US14/766,632 patent/US20150376190A1/en not_active Abandoned
- 2014-02-11 LT LTEP14708987.4T patent/LT2953941T/lt unknown
- 2014-02-11 PT PT147089874T patent/PT2953941T/pt unknown
- 2014-02-11 UA UAA201508755A patent/UA117362C2/uk unknown
- 2014-02-11 HR HRP20171030TT patent/HRP20171030T1/hr unknown
-
2015
- 2015-03-18 US US14/661,797 patent/US9371331B2/en active Active
- 2015-08-28 US US14/839,273 patent/US9469646B2/en not_active Ceased
-
2016
- 2016-05-16 US US15/155,749 patent/US9980952B2/en active Active
- 2016-09-06 US US15/257,275 patent/US10016405B2/en active Active
-
2017
- 2017-07-05 CY CY20171100718T patent/CY1119060T1/el unknown
-
2018
- 2018-01-24 US US15/878,663 patent/USRE47428E1/en active Active
- 2018-05-31 US US15/994,005 patent/US20190125737A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506985A5 (OSRAM) | ||
| JP2017509689A5 (OSRAM) | ||
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| JP2015535277A5 (OSRAM) | ||
| JP2014508811A5 (OSRAM) | ||
| JP2018519323A5 (OSRAM) | ||
| TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
| JP2016516043A5 (OSRAM) | ||
| WO2016097869A4 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| EA200970856A1 (ru) | Ингибиторы пути хеджхога | |
| JP2017519781A5 (OSRAM) | ||
| JP2017501237A5 (OSRAM) | ||
| EA201071232A1 (ru) | Триазины как ингибиторы киназы pi3 и mtor | |
| JP2017511321A5 (OSRAM) | ||
| EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| JP2016513660A5 (OSRAM) | ||
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| JP2014520898A5 (OSRAM) | ||
| JP2013542261A5 (OSRAM) | ||
| EA201001687A1 (ru) | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) | |
| RU2015143843A (ru) | Ингибиторы гистондеацетилазы | |
| JP2015515961A5 (OSRAM) | ||
| JP2010532387A5 (OSRAM) | ||
| JP2013523814A5 (OSRAM) |